{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:37:44Z","timestamp":1765600664246,"version":"3.48.0"},"reference-count":24,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse the characteristics of patients diagnosed with spinal muscular atrophy in Spain, and to revise data on disease management and use of resources in both public and private healthcare centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective multicentre database analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>870 admission records registered between 1997 and 2015 with a diagnosis of spinal muscular atrophy were extracted from a Spanish claims database that includes hospital inpatient and outpatient admissions from 313 public and 192 private hospitals in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Admission files corresponded to 705 patients; 61.99% were males and 38.01% females. Average patient age was 37 years. Disease comorbidities registered during the admission consistently included hypertension, scoliosis and respiratory failures, all associated with the standard disease course. Regarding disease management at the hospital level, patients were mostly admitted through scheduled appointments (58.16%), followed by emergency admissions (41.72%), and into neurology services in 17% of the cases. Mean hospitalisation time was 10.45 days and in-hospital mortality reached 5.29%. The overall direct medical costs of spinal muscular atrophy were \u20ac291\u2009525, excluding medication. The average annual cost per admission was \u20ac6274, with large variations likely to reflect disease complexity and that increases with length of stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The rarity of the disease difficulties the study of demographics and management; yet, an analysis of patient characteristics provides necessary information that can be used by governments to establish more efficient healthcare protocols. This study reflects the impact that individual needs and disease severity can have in disease burden calculations. Forthcoming decision-making policies should take into account medical costs and its variability, as well as pharmaceutical expenses and indirect costs. To our knowledge, this is the first study evaluating the use of healthcare resources of patients with spinal muscular atrophy in Spain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-031271","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T21:45:25Z","timestamp":1574372725000},"page":"e031271","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-0999","authenticated-orcid":false,"given":"Josep","family":"Darb\u00e0","sequence":"first","affiliation":[{"name":"Department of Economics, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Mars\u00e0","sequence":"additional","affiliation":[{"name":"Department of Health Economics, BCN Health Economics & Outcomes Research SL, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"2025121220334428000_9.11.e031271.1","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s11136-018-1945-x","article-title":"Measuring quality of life in children with spinal muscular atrophy: a systematic literature review","volume":"27","author":"Vaidya","year":"2018","journal-title":"Qual Life Res"},{"key":"2025121220334428000_9.11.e031271.2","unstructured":"Spinal dystrophy association. Available: https:\/\/www.mda.org [Accessed 15 Feb 2019]."},{"key":"2025121220334428000_9.11.e031271.3","first-page":"113","article-title":"Proximal spinal muscular atrophy: current orthopedic perspective","volume":"6","author":"Haaker","year":"2013","journal-title":"Appl Clin Genet"},{"key":"2025121220334428000_9.11.e031271.4","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807305673"},{"key":"2025121220334428000_9.11.e031271.5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jval.2018.03.002","article-title":"The problem of rarity: estimation of prevalence in rare disease","volume":"21","author":"Auvin","year":"2018","journal-title":"Value Health"},{"key":"2025121220334428000_9.11.e031271.6","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.74"},{"key":"2025121220334428000_9.11.e031271.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025121220334428000_9.11.e031271.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0695-0","article-title":"Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain","volume":"12","author":"L\u00f3pez-Bastida","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025121220334428000_9.11.e031271.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020907","article-title":"Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives","volume":"8","author":"Farrar","year":"2018","journal-title":"BMJ Open"},{"key":"2025121220334428000_9.11.e031271.10","unstructured":"Certificates of Discharge of the National Health System Register . Claims database minimum basic data set (CMBD). Available: https:\/\/www.mscbs.gob.es\/estadEstudios\/estadisticas\/cmbdAnteriores.htm [Accessed 8 Oct 2018]."},{"key":"2025121220334428000_9.11.e031271.11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s41669-018-0093-0","article-title":"High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (Sma1): retrospective analysis of the kids' inpatient database (kid)","volume":"3","author":"Cardenas","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"2025121220334428000_9.11.e031271.12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","article-title":"The economic burden of spinal muscular atrophy","volume":"19","author":"Armstrong","year":"2016","journal-title":"J Med Econ"},{"key":"2025121220334428000_9.11.e031271.13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ncl.2015.07.005","article-title":"Progressive muscular atrophy","volume":"33","author":"Liewluck","year":"2015","journal-title":"Neurol Clin"},{"key":"2025121220334428000_9.11.e031271.14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JND-170292","article-title":"An overview of the cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members","volume":"5","author":"Belter","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2025121220334428000_9.11.e031271.15","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-20-06-393"},{"key":"2025121220334428000_9.11.e031271.16","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.nmd.2017.06.153","article-title":"Scoliosis is an inescapable comorbidity in SMA type II. A single center experience","volume":"27","author":"Catteruccia","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2025121220334428000_9.11.e031271.17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.recesp.2015.11.036","article-title":"Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study","volume":"69","author":"Men\u00e9ndez","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"2025121220334428000_9.11.e031271.18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2025121220334428000_9.11.e031271.19","doi-asserted-by":"crossref","unstructured":"Teynor M , Hou Q , Zhou J , et al . Healthcare resource use in patients with diagnosis of spinal muscular atrophy (SMA) in Optum\u2122 U.S. claims database (P4.158). Neurology 2017;88.","DOI":"10.1212\/WNL.88.16_supplement.P4.158"},{"key":"2025121220334428000_9.11.e031271.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"2025121220334428000_9.11.e031271.21","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462303000515"},{"key":"2025121220334428000_9.11.e031271.22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.12927\/cjnl.2016.24805","article-title":"Nurse leaders' perceptions of influence of organizational restructuring on evidence-informed decision-making","volume":"29","author":"Spiers","year":"2016","journal-title":"Nurs Leadersh"},{"key":"2025121220334428000_9.11.e031271.23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jclinepi.2017.09.023","article-title":"Decision-Making frameworks and considerations for informing coverage decisions for healthcare interventions: a critical interpretive synthesis","volume":"94","author":"Morgan","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2025121220334428000_9.11.e031271.24","doi-asserted-by":"crossref","unstructured":"Pantoja T , Barreto J , Panisset U . Improving public health and health systems through evidence informed policy in the Americas. BMJ 2018;362.doi:10.1136\/bmj.k2469","DOI":"10.1136\/bmj.k2469"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-031271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:33:57Z","timestamp":1765600437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-031271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,21]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/bmjopen-2019-031271"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-031271","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}